FDA approves Abbott CGMs for use during medical imaging

Abbott (NYSE:ABT) today announced a significant regulatory milestone that could make common medical procedures easier for people with diabetes.

Drug Delivery Business News, reports today that the FDA cleared the removal of the imaging contradiction for the FreeStyle Libre 2 and 3 continuous glucose monitors (CGMs) for procedures like X-rays, CT scans and MRIs. Abbott said it makes its systems the first and only patient-applied CGM sensors approved for these screenings.

Imaging procedures often come as part of diabetes care, Abbott said, especially as diabetes can cause a number of medical complications. The company rigorously tested its Libre 2 and 3 sensors to ensure they remain effective after radiologic procedures. This FDA clearance comes with no changes made to the sensor, too.

Sign up for Blog Updates